查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1717887

思覺失調症類型、治療層級、作用機制、製劑類型、最終用戶、患者環境、患者人口統計分類 - 2025-2030 年全球預測

Schizophrenia Therapeutics Market by Type, Therapeutic Class, Mechanism of Action, Formulation Type, End Users, Patient Settings, Patient Demographics - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年思覺失調症藥物市場價值為55.9億美元，2024年將達58.9億美元，複合年成長率為5.47%，到2030年將達到81.2億美元。

主要市場統計數據
基準年2023年 55.9億美元
預計2024年 58.9億美元
預測年份 2030 81.2億美元
複合年成長率（%） 5.47%

管理和治療思覺失調症一直是一個長期的挑戰，需要對臨床科學和患者照護有深入的了解。近幾十年來，該領域的研究和實踐取得了長足發展，將創新的科學方法與富有同情心的患者支持相結合。本執行摘要深入探討了當前的治療前景，重點介紹了治療方法重塑治療治療方法的現有治療方法和新興療法。

我們對神經生物學和心理健康的理解不斷進步，從而增強了治療通訊協定，並強調個人化醫療。新興的臨床見解加上正在進行的研究為相關人員提供了大量數據，從而改善了診斷、治療計劃和結果評估。該報告介紹了思覺失調症藥物領域的主要趨勢、細分、區域分析和公司績效數據，旨在為決策者和專業人士提供全面的指南。

在快速發展的環境中，不斷改進治療方法至關重要。現在，相關人員比以往任何時候都更需要利用尖端策略，與研究機構、醫療保健提供者和產業合作夥伴密切合作，推動患者照護和臨床結果的有意義的進步。

思覺失調症治療的變革

思覺失調症藥物治療的最新趨勢表明，模式轉移融合了新的臨床實踐和技術創新。該行業正在經歷變革時期，傳統方法正在與先進的科學研究和數位健康解決方案相結合。創新的治療方法、以患者為中心的護理模式和真實世界的證據正在全面重新定義預防策略和長期管理解決方案。

研究人員和臨床醫生擴大採用數位平台進行患者監測和診斷，從而提高治療決策的準確性和效率。精準醫療技術與人工智慧的結合使得人們能夠更深入地了解患者的反應，而來自臨床研究的新興數據則推動著治療通訊協定的演變。這種動態轉變正在為從急性護理到長期管理的連續護理鋪平道路，從而改善患者的生活品質。

該行業現在面臨多學科協作和跨職能洞察至關重要的未來。隨著相關人員從傳統的治療方法轉向更全面、技術主導的模式，整個醫療領域正在經歷重大變革時期，這些模式有望提高治療依從性、改善臨床結果並持續促進醫療保健服務的成長。

對塑造市場格局的細分市場的詳細洞察

對市場區隔的詳細分析為了解思覺失調症藥物的各個方面提供了寶貴的見解。從市場類型來看，非藥物療法和藥物療法都受到了廣泛關注。在非藥物治療領域，認知行為療法、電痙攣療法和家庭治療等方法在患者管理中越來越受到認可，為從整體角度解決心理健康問題提供了選擇。在藥理學方面，注射藥物和口服藥物的分類為針對不同患者需求和依從性因素的客製化治療方法鋪平了道路。

除了治療方法類型之外，治療層級之間也有明顯區別：抗精神病藥物、情緒穩定劑和選擇性血清素再回收抑制劑。抗精神病藥物特別分為第一代和第二代，反映了配方的演變及其對症狀緩解和副作用的影響。根據臨床療效和個別患者反應情況，每類藥物對治療策略都有獨特的貢獻。

此外，根據作用機制分析細分時，還會出現更多細微差別。這些包括多巴胺受體拮抗劑、麩胺酸調變器以及血清素和多巴胺活性調變器，每種藥物都表現出影響治療結果的不同動態特性。此外，透過插入物和貼片、液體和固態錠劑的視角對配方類型進行了嚴格審查，強調了輸送機制如何顯著影響患者的依從性。細分策略也擴展到調查居家照護機構、醫院、精神科診所和研究機構等最終用戶。最後，患者環境（無論是住院還是門診病人）以及患者人口統計（包括成人、老年和兒童）提供了影響整體市場動態的不同患者概況的全面視圖。每個細分參數都提供了精確的見解，幫助相關人員更好地了解市場的複雜性並相應地調整他們的策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球精神疾病盛行率上升
      • 擴大政府措施和宣傳活動，提高人們對精神疾病的認知
    • 限制因素
      • 對產品召回和不利事件的擔憂
    • 機會
      • 針對不同類型思覺失調症的標靶治療進展
      • 口服抗精神病藥物臨床試驗增加凸顯其潛力
    • 任務
      • 抗精神病藥物的副作用問題
  • 市場區隔分析
    • 類型：注射劑在持續釋放藥物方面的重要性日益凸顯，有助於提高患者依從性
    • 治療層級：具有更廣泛作用機制的第二代抗精神病藥物的採用日益增加。
    • 作用機轉：藉由增加血清素活性並同時調節多巴胺，增強血清素和多巴胺活性調節劑的效果。
    • 配方類型：對於吞嚥困難或需要調整劑量的患者，液體溶液的需求日益增加
    • 最終使用者：多種治療方法的綜合護理計劃擴大了思覺失調症藥物在精神病診所的應用
    • 病人環境：擴大思覺失調症物在住院治療的益處
    • 患者人口統計：思覺失調症藥物的個人化治療方法對老年患者很重要
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章思覺失調症藥物市場（按類型）

  • 非藥物治療
    • 認知行為治療（CBT）
    • 電痙攣療法（ECT）
    • 家庭治療
  • 藥物治療
    • 注射藥物
    • 口服藥物

第7章思覺失調症藥物市場（依治療層級）

  • 抗精神病藥物
    • 第一代抗精神病藥物
    • 第二代抗精神病藥物
  • 情緒穩定劑
  • 選擇性血清素再回收抑制劑

第8章思覺失調症藥物市場（依作用機制）

  • 多巴胺受體拮抗劑
  • 麩胺酸調變器
  • 血清素/多巴胺活性調節劑

第9章思覺失調症治療藥物市場（依處方類型）

  • 插入件和補丁
  • 液體溶液
  • 固態錠劑

第 10 章思覺失調症藥物市場（按最終用戶）

  • 居家照護環境
  • 醫院
  • 心理健康診所
  • 研究機構

第 11 章思覺失調症藥物市場（依患者環境）

  • 住院護理
  • 門診護理

第 12 章思覺失調症藥物市場（依患者人口統計）

  • 成年患者
  • 老年患者
  • 兒科患者

13.美洲思覺失調症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太地區思覺失調症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

15. 歐洲、中東和非洲思覺失調症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Alkermes Plc
  • Amneal Pharmaceuticals, LLC
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • BioXcel Therapeutics, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Delpor, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Gedeon Richter Plc
  • GlaxoSmithKline plc.
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lundbeck A/S
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Lyndra Therapeutics Inc
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Neurocrine Biosciences, Inc.
  • Novartis AG
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Holdings, Inc.
  • Sanofi SA
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Vanda Pharmaceuticals Inc.
Product Code: MRR-8E22B61932B8

The Schizophrenia Therapeutics Market was valued at USD 5.59 billion in 2023 and is projected to grow to USD 5.89 billion in 2024, with a CAGR of 5.47%, reaching USD 8.12 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 5.59 billion
Estimated Year [2024] USD 5.89 billion
Forecast Year [2030] USD 8.12 billion
CAGR (%) 5.47%

The management and treatment of schizophrenia have long presented challenges that require a deep understanding of both clinical science and patient care. In recent decades, research and practice in this field have evolved significantly, combining innovative scientific approaches with compassionate patient support. This executive summary offers an in-depth exploration of the current therapeutics landscape, addressing both established and emerging modalities that are reshaping treatment paradigms.

Advancements in the understanding of neurobiology and mental health have led to enhanced treatment protocols that emphasize personalized care. Novel clinical insights, coupled with ongoing research, have provided stakeholders with a wealth of data, allowing for improved diagnosis, treatment planning, and outcome evaluation. This document aims to serve as a comprehensive guide for decision-makers and experts alike, presenting key trends, segmentation insights, regional analysis, and company performance data for a clear strategic focus in the field of schizophrenia therapeutics.

In this rapidly evolving environment, continuous improvement of therapeutic methodologies is imperative. Stakeholders are now, more than ever, encouraged to leverage cutting-edge strategies and collaborate closely with research institutions, healthcare providers, and industry partners to drive meaningful progress in patient care and clinical outcomes.

Transformative Shifts in Schizophrenia Therapeutics

Recent trends within the field of schizophrenia therapeutics have signaled a paradigm shift towards integrating both novel clinical practices and technological innovations. The industry is witnessing a transformative phase where traditional approaches are being augmented with advanced scientific research and digital health solutions. Innovative treatment methodologies, patient-centered care models, and real-world evidence have collectively redefined both preventative strategies and long-term management solutions.

Researchers and clinicians are increasingly adopting digital platforms for patient monitoring and diagnosis, thereby enhancing the accuracy and efficiency of treatment decisions. The integration of precision medicine techniques and artificial intelligence has allowed for more granular insights into patient responses, while emerging data from clinical studies is driving the evolution of therapeutic protocols. This dynamic shift is paving the way for a continuum of care that spans acute treatment phases to long-term management, ensuring a better quality of life for patients.

The industry now faces a future where interdisciplinary collaboration and cross-functional insights are essential. As stakeholders transition from conventional treatment regimens to more holistic, technology-driven models, the entire therapeutic landscape is undergoing a profound transformation that promises improved treatment adherence, superior clinical outcomes, and sustainable growth in healthcare delivery.

In-Depth Segmentation Insights Shaping the Market Landscape

A granular analysis of the market segmentation provides valuable insights into the diverse dimensions of schizophrenia therapeutics. By examining the market based on type, significant attention has been directed towards both non-pharmacological and pharmacological therapies. In the realm of non-pharmacological treatments, methods such as Cognitive-Behavioral Therapy, Electroconvulsive Therapy, and Family Therapy are playing an increasingly recognized role in patient management, offering alternatives that address mental health from a holistic standpoint. On the pharmacological front, the division into injectable and oral medications has paved the way for tailored treatment regimens that cater to different patient needs and compliance factors.

Beyond therapy types, the therapeutic class segmentation delineates a clear distinction among antipsychotics, mood stabilizers, and selective serotonin reuptake inhibitors. The antipsychotics category, in particular, is segmented further into first-generation and second-generation compounds, reflecting the evolution of drug formulations and their impact on symptomatic relief and side effect profiles. Each class contributes uniquely to treatment strategies, informed by clinical efficacy and individual patient response profiles.

Further nuances emerge when the segmentation is analyzed based on the mechanism of action. This includes an emphasis on dopamine receptor antagonists, glutamate modulators, and serotonin dopamine activity modulators, each indicative of a distinct pharmacodynamic property that influences therapeutic outcomes. Additionally, formulation type is critically examined through the lenses of inserts and patches, liquid solutions, and solid tablets, revealing how delivery mechanisms can significantly affect patient adherence. The segmentation strategy also extends to the exploration of end users across homecare settings, hospitals, mental health clinics, and research institutes. Lastly, patient settings, whether inpatient or outpatient care, and patient demographics, including adult, geriatric, and pediatric patients, provide a comprehensive view of the diverse patient profiles that influence the overall market dynamic. Each segmentation parameter offers precise insights that help stakeholders better understand the market's complexity and tailor strategies accordingly.

Based on Type, market is studied across Non-Pharmacological Therapies and Pharmacological Therapies. The Non-Pharmacological Therapies is further studied across Cognitive-Behavioral Therapy (CBT), Electroconvulsive Therapy (ECT), and Family Therapy. The Pharmacological Therapies is further studied across Injectable Medications and Oral Medications.

Based on Therapeutic Class, market is studied across Antipsychotics, Mood Stabilizers, and Selective Serotonin Reuptake Inhibitors. The Antipsychotics is further studied across First-Generation Antipsychotics and Second-Generation Antipsychotics.

Based on Mechanism of Action, market is studied across Dopamine Receptor Antagonists, Glutamate Modulators, and Serotonin Dopamine Activity Modulators.

Based on Formulation Type, market is studied across Inserts and Patches, Liquid Solutions, and Solid Tablets.

Based on End Users, market is studied across Homecare Settings, Hospitals, Mental Health Clinics, and Research Institutes.

Based on Patient Settings, market is studied across Inpatient Care and Outpatient Care.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Key Regional Insights Influencing Market Dynamics

A regional perspective unveils critical differences and emerging opportunities within the global schizophrenia therapeutics market. In the Americas, the landscape is marked by a robust integration of clinical research and a strong emphasis on innovation, with established healthcare infrastructures supporting wide-spread adoption of both traditional and emerging treatment modalities. These markets benefit from a well-developed environment of regulatory support, a competitive pharmaceutical industry, and active investments in mental health research, which collectively drive the adoption of new therapies.

Turning attention to regions spanning Europe, the Middle East, and Africa, one finds a diverse mix of market conditions. European nations, with their long-standing traditions in clinical research and high-quality healthcare provisions, lead in the adoption of innovative therapeutics, bridging the gap between novel scientific breakthroughs and patient care. Simultaneously, regions in the Middle East and Africa are rapidly evolving, with increasing investments in healthcare infrastructure and a growing focus on mental health awareness. The dynamic interplay between emerging markets and traditional systems in these areas presents both challenges and significant growth opportunities.

In the Asia-Pacific region, the market is characterized by rapid development and a surge in research investments. This region stands out for its expanding patient base coupled with an evolving regulatory framework, which together create a fertile environment for the introduction and acceptance of advanced therapeutic solutions. The collective insights from these regions reveal a complex, yet opportunistic global market where varying socio-economic and regulatory factors converge, ultimately driving both competitive intensity and innovation in schizophrenia therapeutics.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Analysis of Key Company Performances

An analysis of the leading companies in schizophrenia therapeutics offers a window into competitive dynamics and strategic innovations within the market. Prominent firms such as AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Plc, and Amneal Pharmaceuticals, LLC have established themselves as benchmarks in the pursuit of novel treatment paradigms. Esteemed organizations like Astellas Pharma Inc., AstraZeneca plc, and BioXcel Therapeutics, Inc. continue to invest heavily in research and development, ensuring that their therapeutic portfolios remain at the forefront of innovation.

In addition, companies including Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, and Delpor, Inc. are recognized for their commitment to clinical excellence and the introduction of next-generation therapies. Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, and Gedeon Richter Plc further reinforce the market's competitive behavior by continually adapting to evolving clinical guidelines and market demands.

Other influential players such as GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lundbeck A/S, and Lupin Limited, alongside emerging innovators like Luye Pharma Group Ltd, Lyndra Therapeutics Inc, and Meiji Holdings Co., Ltd., are leveraging strategic partnerships and technological advancements to extend their market reach. The industry is also shaped by the contributions of Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Vanda Pharmaceuticals Inc. Each of these companies brings a unique blend of innovation, expertise, and a commitment to patient care, collectively driving a proactive evolution in therapeutic solutions across the market.

The report delves into recent significant developments in the Schizophrenia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Acadia Pharmaceuticals Inc., Alkermes Plc, Amneal Pharmaceuticals, LLC, Astellas Pharma Inc., AstraZeneca plc, BioXcel Therapeutics, Inc., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Cipla Limited, Delpor, Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Gedeon Richter Plc, GlaxoSmithKline plc., Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lundbeck A/S, Lupin Limited, Luye Pharma Group Ltd, Lyndra Therapeutics Inc, Meiji Holdings Co., Ltd., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Reviva Pharmaceuticals Holdings, Inc., Sanofi S.A, Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Vanda Pharmaceuticals Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are advised to adopt a multifaceted strategy designed to harness emerging trends and foster sustainable growth in the schizophrenia therapeutics market. Decision-makers should prioritize an expansive research and development agenda that integrates the latest breakthroughs in pharmacological and non-pharmacological treatments. Fostering a culture of innovation through cross-functional collaborations and strategic partnerships will be imperative for staying ahead of evolving clinical standards.

Investments in digital health technologies and data analytics are also crucial for improving patient outcome analytics and ensuring that treatment protocols are timely, effective, and responsive to patient needs. Leaders should engage with healthcare practitioners, academic researchers, and technology innovators to build robust platforms that support advanced diagnostic and therapeutic tools. Building these collaborations not only enhances research capabilities but also enables companies to adapt quickly to regulatory changes and evolving market expectations.

Additionally, a proactive engagement with regulatory bodies and patient advocacy groups will be essential in creating an environment conducive to the rapid adoption of novel therapies. By capitalizing on the comprehensive insights provided through detailed market segmentation, regional explorations, and competitive company analyses, industry stakeholders can tailor their strategies to address both current challenges and future opportunities. A commitment to continuous learning, adaptive strategies, and patient-centered innovations will place industry leaders at the forefront of the therapeutic evolution in schizophrenia, ultimately leading to enhanced market performance and improved patient outcomes.

Conclusion: Synthesizing Market Trends and Future Prospects

The landscape of schizophrenia therapeutics is witnessing a rapid evolution characterized by technological innovation, comprehensive segmentation strategies, and active global participation. An integration of non-pharmacological and pharmacological treatments, supported by detailed analysis and robust regional insights, has provided stakeholders with a holistic view of the market dynamics. These trends not only highlight the progress made but also shed light on areas where further innovations could potentially reshape patient care.

In approaching the complexities of this market, the synthesis of intricate segmentation details and expansive regional insights reveals a promising yet challenging environment. The competitive spirit of leading pharmaceutical and biotechnological companies underscores the importance of a coordinated global strategy. As initiatives align more closely with advanced data analytics, digital strategies, and innovative treatment options, the future of schizophrenia therapeutics appears poised for remarkable transformation.

Overall, the clinical and market landscapes are converging to create an ecosystem where research, innovation, and patient-centered care operate in harmony. The strategic insights outlined reinforce the idea that a proactive, informed, and agile approach will be essential for stakeholders aiming to capture market opportunities and set new benchmarks in therapeutic excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of mental health disorders across the globe
      • 5.1.1.2. Growing government initiatives and campaigns for awareness of mental illness
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with the product recall and adverse findings in medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements for developing targeted therapies for different types of schizophrenia
      • 5.1.3.2. Rising potential with increasing clinical trials for oral antipsychotic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Issues related to adverse side effects associated with antipsychotic drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing significance of injectable medications for sustained release of medication that can enhance adherence
    • 5.2.2. Therapeutic Class: Increasing adoption of second-generation antipsychotics for broader mechanism of action that targets
    • 5.2.3. Mechanism of Action: Growing benefits of serotonin dopamine activity modulators owing to enhancing serotonin activity while simultaneously modulating dopamine
    • 5.2.4. Formulation Type: Growing need of liquid solutions due to swallowing difficulties or those requiring dose adjustments
    • 5.2.5. End Users: Extending applications of schizophrenia therapeutics in mental health clinics owing to comprehensive care plans for various therapeutic modalities
    • 5.2.6. Patient Settings: Proliferating benefits of schizophrenia therapeutics medications for inpatient care
    • 5.2.7. Patient Demographics: High importance of schizophrenia therapeutics for geriatric patients owing to tailored therapeutic approaches
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Schizophrenia Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Therapies
    • 6.2.1. Cognitive-Behavioral Therapy (CBT)
    • 6.2.2. Electroconvulsive Therapy (ECT)
    • 6.2.3. Family Therapy
  • 6.3. Pharmacological Therapies
    • 6.3.1. Injectable Medications
    • 6.3.2. Oral Medications

7. Schizophrenia Therapeutics Market, by Therapeutic Class

  • 7.1. Introduction
  • 7.2. Antipsychotics
    • 7.2.1. First-Generation Antipsychotics
    • 7.2.2. Second-Generation Antipsychotics
  • 7.3. Mood Stabilizers
  • 7.4. Selective Serotonin Reuptake Inhibitors

8. Schizophrenia Therapeutics Market, by Mechanism of Action

  • 8.1. Introduction
  • 8.2. Dopamine Receptor Antagonists
  • 8.3. Glutamate Modulators
  • 8.4. Serotonin Dopamine Activity Modulators

9. Schizophrenia Therapeutics Market, by Formulation Type

  • 9.1. Introduction
  • 9.2. Inserts and Patches
  • 9.3. Liquid Solutions
  • 9.4. Solid Tablets

10. Schizophrenia Therapeutics Market, by End Users

  • 10.1. Introduction
  • 10.2. Homecare Settings
  • 10.3. Hospitals
  • 10.4. Mental Health Clinics
  • 10.5. Research Institutes

11. Schizophrenia Therapeutics Market, by Patient Settings

  • 11.1. Introduction
  • 11.2. Inpatient Care
  • 11.3. Outpatient Care

12. Schizophrenia Therapeutics Market, by Patient Demographics

  • 12.1. Introduction
  • 12.2. Adult Patients
  • 12.3. Geriatric Patients
  • 12.4. Pediatric Patients

13. Americas Schizophrenia Therapeutics Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Schizophrenia Therapeutics Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Schizophrenia Therapeutics Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Intra-cellular therapies reports positive phase 3 results for CAPLYTA in schizophrenia relapse prevention
    • 16.3.2. Teva unveils promising results from SOLARIS trial and real-world UZEDY analysis for schizophrenia treatment
    • 16.3.3. Leal therapeutics secures USD 45 million to advance schizophrenia and CNS disorder therapies
    • 16.3.4. Monument Therapeutics secures GBP 1M investment to advance schizophrenia treatment
    • 16.3.5. FDA approves Bristol Myers Squibb's new muscarinic agonist COBENFY for adults
    • 16.3.6. AbbVie's acquisition of Cerevel enhances its neuroscience pipeline and increase schizophrenia therapeutics
    • 16.3.7. FDA aligns with Reviva pharmaceuticals on brilaroxazine phase 3 trials for schizophrenia
    • 16.3.8. Lupin gains FDA approval for generic aripiprazole tablets, expanding U.S. CNS Presence
    • 16.3.9. Bristol Myers Squibb's acquisition of Karuna Therapeutics enhances schizophrenia treatment landscape
    • 16.3.10. Boehringer Ingelheim's schizophrenia treatment secures FDA breakthrough therapy status
    • 16.3.11. Lyndra Therapeutics reports positive phase 3 outcomes for oral weekly risperidone in schizophrenia
    • 16.3.12. Karuna Therapeutics' KarXT receives FDA NDA acceptance for schizophrenia treatment
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. Sanofi S.A.
    • 16.4.2. Lupin Limited
    • 16.4.3. Boehringer Ingelheim International GmbH
    • 16.4.4. Bristol-Myers Squibb and Company

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Acadia Pharmaceuticals Inc.
  • 3. Alkermes Plc
  • 4. Amneal Pharmaceuticals, LLC
  • 5. Astellas Pharma Inc.
  • 6. AstraZeneca plc
  • 7. BioXcel Therapeutics, Inc.
  • 8. Boehringer Ingelheim International GmbH
  • 9. Bristol Myers Squibb Company
  • 10. Cipla Limited
  • 11. Delpor, Inc.
  • 12. Dr. Reddy's Laboratories Ltd.
  • 13. Eli Lilly and Company
  • 14. Gedeon Richter Plc
  • 15. GlaxoSmithKline plc.
  • 16. Glenmark Pharmaceuticals Limited
  • 17. Johnson & Johnson Services, Inc.
  • 18. Lundbeck A/S
  • 19. Lupin Limited
  • 20. Luye Pharma Group Ltd
  • 21. Lyndra Therapeutics Inc
  • 22. Meiji Holdings Co., Ltd.
  • 23. Merck & Co., Inc.
  • 24. Neurocrine Biosciences, Inc.
  • 25. Novartis AG
  • 26. Otsuka Holdings Co., Ltd.
  • 27. Pfizer Inc.
  • 28. Reviva Pharmaceuticals Holdings, Inc.
  • 29. Sanofi S.A
  • 30. Sumitomo Pharma Co., Ltd.
  • 31. Sun Pharmaceutical Industries Limited
  • 32. Takeda Pharmaceutical Company Limited
  • 33. Teva Pharmaceutical Industries Ltd.
  • 34. Torrent Pharmaceuticals Ltd.
  • 35. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. SCHIZOPHRENIA THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. SCHIZOPHRENIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SCHIZOPHRENIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SCHIZOPHRENIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309.